This correlated with a decrease in desmoglein-2 protein expression, as determined by Western blotting (figure 1B), following DSG2-siRNA treatment, showing DSG2 down-regulation similar to levels expressed by SSc-MVECs (shown in lanes 1, 2 and 3 on the right). This evidence concerns the gene DSG2 and systemic sclerosis.